Unsatisfactory Facility Inspection Responses
Severity: majorThe manufacturing facility must provide satisfactory responses to deficiencies identified during the FDA 483 inspection prior to the resubmission of the application. Resolution of these findings is critical for approvability and may involve re-inspection.
Recommended response: Collaborate with the manufacturing facility to promptly address all FDA 483 observations and submit comprehensive responses to the FDA office indicated on the 483.
Unfavorable Clinical Benefit-Risk Balance for Type 1 Diabetes
Severity: criticalThe submitted clinical data for NNC0148-0287 in adults with type 1 diabetes demonstrates an unacceptably higher risk of clinically meaningful hypoglycemia compared to the daily basal insulin comparator, without evidence of sufficient compensatory benefit. This renders the benefit-risk balance unfavorable.
Recommended response: Provide new clinical data to demonstrate a favorable benefit-risk profile for NNC0148-0287 in type 1 diabetes. This should include optimizing the dosing and titration algorithm and assessing other patient-important outcomes. Request a post-action meeting to discuss the design of a new clinical study.
Chemistry, Manufacturing, and Controls (CMC) Deficiencies
Severity: majorSpecific deficiencies related to Chemistry, Manufacturing, and Controls were identified. Details are redacted in the provided letter, but these issues require resolution for application approval.
Recommended response: Address all specific CMC deficiencies once the unredacted details are available. This may involve process adjustments, data generation, or updated documentation.
Proprietary Name Resubmission
Severity: minorThe proposed proprietary name was found acceptable pending approval of the application. It must be resubmitted when responding to the application deficiencies.
Recommended response: Resubmit the proposed proprietary name as part of the complete response to the application deficiencies.
Inadequate Safety Update Submission
Severity: majorA comprehensive safety update, as described in 21 CFR 314.50(d)(5)(vi)(b), is required. This includes detailed changes in the safety profile, retabulation of adverse events, case report forms for deaths/serious adverse events, updated exposure information, and a summary of worldwide safety experience.
Recommended response: Prepare and submit a complete safety update that meticulously addresses all specified requirements, including new data, retabulations, narrative summaries, and worldwide experience.
Cited: 21 CFR 314.50(d)(5)(vi)(b)
Prescribing Information Review Pending
Severity: infoThe FDA reserves comment on the proposed labeling until other application deficiencies are resolved. The sponsor is encouraged to review labeling resources and utilize the Selected Requirements for Prescribing Information (SRPI) checklist for future revisions.
Recommended response: Proactively review FDA labeling guidance and the SRPI checklist to ensure future labeling submissions conform to regulatory requirements, especially once clinical and CMC issues are resolved.
Cited: 21 CFR 601.14(b)
